SIRT1 catalytic activity has little effect on tumor, formation and metastases in a mouse model of breast cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Clark Knowles, Katherine V ^a   Dewar Darch, Danielle ^a   Jardine, Karen E ^a   McBurney, Michael W ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER GROWTH; CANCER TISSUE; CATALYSIS; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; SURVIVAL; TRANSGENE;

ANIMALS; BREAST NEOPLASMS; CATALYSIS; DISEASE MODELS, ANIMAL; FEMALE; LUNG NEOPLASMS; MALE; MICE; SIRTUIN 1;

EID: 84896722565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082106     Document Type: Article

References (49)

1. Anderson RM, Weindruch R (2012) The caloric restriction paradigm: implications for healthy human aging. Am J Hum Biol 24: 101-106. doi:10.1002/ajhb.22243. PubMed: 22290875.
2. Lin SJ, Defossez PA, Guarente L (2000) Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289: 2126-2128. doi:10.1126/science.289.5487.2126. PubMed: 11000115.
3. Rogina B, Helfand SL (2004) Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A 101: 15998-16003. doi:10.1073/pnas.0404184101. PubMed: 15520384. (Pubitemid 39507916)
4. Boily G, Seifert EL, Bevilacqua L, He XH, Sabourin G et al. (2008) SirT1 Regulates Energy Metabolism and Response to Caloric Restriction in Mice. PLOS ONE 3: e1759. doi:10.1371/journal.pone.0001759. PubMed: 18335035.
5. Vaziri H, Dessain SK, Eaton EN, Imai SI, Frye RA et al. (2001) hSIR2(SIRT1) Functions as an NAD-Dependent p53 Deacetylase. Cell 107: 149-159. doi:10.1016/S0092-8674(01)00527-X. PubMed: 11672523. (Pubitemid 33035942)
6. Longo VD (2008) Linking sirtuins, IGF-I signaling, and starvation. Exp Gerontol44: 70-74. PubMed: 18638538.
7. Jang SH, Min KW, Paik SS, Jang KS (2012) Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol 65: 735-739. doi:10.1136/jclinpath-2012-200685. PubMed: 22554968.
8. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S et al. (2008) The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer. Growth - PLOS ONE 3: e2020. doi:10.1371/journal.pone.0002020.
9. Wang RH, Sengupta K, Li C, Kim HS, Cao L et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323. doi:10.1016/j.ccr.2008.09.001. PubMed: 18835033.
10. Beane J, Cheng L, Soldi R, Zhang X, Liu G et al. (2012) SIRT1 pathway dysregulation in the smoke-exposed airway epithelium and lung tumor tissue. Cancer Res 72: 5702-5711. doi:10.1158/0008-5472.CAN-12-1043. PubMed: 22986747.
11. Herranz D, Maraver A, Cañamero M, Gómez-López G, Inglada-Pérez L et al. (2013) SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene epub ahead of print. PubMed: 22986535.
12. Luo J, Nikolaev AY, Imai S, Chen D, Su F et al. (2001) Negative Control of p53 by Sir2alpha Promotes Cell Survival under Stress. Cell 107: 137-148. doi:10.1016/S0092-8674(01)00524-4. PubMed: 11672522. (Pubitemid 33035941)
13. Chen WY, Wang DH, Yen RC, Luo J, Gu W, et al. (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448. S0092-8674(05)00815-9 [pii];Available online at: 10.1016/j.cell.2005.08.011 [doi]
14. Huffman DM, Grizzle WE, Bamman MM, Kim Js, Eltoum IA et al. (2007) SIRT1 Is Significantly Elevated in Mouse and Human Prostate. Cancer - Cancer Res 67: 6612-6618. doi:10.1158/0008-5472.CAN-07-0085. Available online at: doi:10.1158/0008-5472.CAN-07-0085
15. Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, et al. (2007) Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2: 1360-1368 (Pubitemid 350176266)
16. Boily G, He XH, Pearce B, Jardine K, McBurney MW (2009) SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28: 2882-2893. doi:10.1038/onc.2009.147. PubMed: 19503100.
17. Roth M, Chen WY (2013) Sorting out functions of sirtuins in cancer. Oncogene epub ahead of print. PubMed: 23604120. onc2013120 . PII;Available: . doi:10.1038/onc.2013.120
18. McBurney MW, Clark-Knowles KV, Caron AZ, Gray DA (2013) SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress. Genes Cancer epub ahead of print. PubMed: 24020004.
19. Sharma A, Gautam V, Costantini S, Paladino A, Colonna G (2012) Interactomic and pharmacological insights on human sirt-1. Front. Pharmacol 3: 40.
20. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ (2007) SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol 210: 161-166. doi:10.1002/jcp.20831. PubMed: 16998810.
21. Wong S, Weber JD (2007) Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J 407: 451-460. doi:10.1042/BJ20070151. PubMed: 17620057. (Pubitemid 350058478)
22. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380. doi:10.1038/sj.emboj.7600244. PubMed: 15152190. (Pubitemid 38954844)
23. Yuan J, Minter-Dykhouse K, Lou Z (2009) A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185: 203-211. doi:10.1083/jcb.200809167. PubMed: 19364925.
24. Wang RH, Zheng Y, Kim HS, Xu X, Cao L et al. (2008) Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32: 11-20. doi:10.1016/j.molcel.2008.09.011. PubMed: 18851829.
25. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, et al. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451: 587-590: nature06515. PubMed: 18235502. PII];10.1038/ nature06515 [doi]. PubMed: 18235502.
26. Kim JE, Chen J, Lou Z Kim JE, Chen J, Lou Z (2008) DBC1 is a negative regulator of SIRT1. Nature 451: 583-586: nature06500. PubMed: 18235501. PII];10.1038/nature06500 [doi]. PubMed: 18235501.
27. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, et al. (2008) SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 135: 907-918.S0092-8674(08)01317-2 [pii];Available online at: 10.1016/j.cell.2008.10.025 [doi]
28. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, et al. (2011) Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42: 204-213. S0046-8177(10)00248-0 [pii];Available online at: 10.1016/j.humpath.2010.05.023 [doi]
29. Wu M, Wei W, Xiao X, Guo J, Xie X et al. (2012) Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol 29: 3240-3249. doi:10.1007/s12032-012-0260-6. PubMed: 22661383.
30. Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T et al. (2012) SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 27: 1726-1732. PubMed: 22470132.
31. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961. PubMed: 1312220.
32. Lin EY, Jones JG, Li P, Zhu L, Whitney KD et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126. doi:10.1016/S0002-9440(10)63568-7. PubMed: 14578209. (Pubitemid 37310040)
33. Seifert EL, Caron AZ, Morin K, Coulombe J, Hong H, et al X. (2012) SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice. FASEB J 26: 555-566. doi:10.1096/fj.11-193979. PubMed: 22006156.
34. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmbäck K et al. (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16: 3097-3104. doi:10.1038/sj.onc.1201869. PubMed: 9671388. (Pubitemid 28318780)
35. Li H, Rajendran GK, Liu N, Ware C, Rubin BP et al. (2007) SirT1 modulates the estrogen-IGF-1 signaling for postnatal development of mammary gland in mice. Breast Cancer Res 9: R1. doi:10.1186/bcr1707. PubMed: 17201918.
36. Morris BJ (2013) Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med [Epub ahead of print]. PubMed: 23104101.
37. Brooks CL, Gu W (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9: 123-128. doi:10.1038/nrc2562. PubMed: 19132007. nrc2562 . PII;Available: . doi:10.1038/nrc2562
38. Bocchinfuso WP, Korach KS (1997) Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 2: 323-334. doi:10.1023/A:1026339111278. PubMed: 10935020.
39. Stingl J (2011) Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2: 85-90. doi:10.1007/s12672-010-0055-1. PubMed: 21761331.
40. Dabrosin C, Palmer K, Muller WJ, Gauldie J (2003) Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat 78: 1-6. doi:10.1023/A:1022133219353. PubMed: 12611451. (Pubitemid 36223011)
41. Yao Y, Li H, Gu Y, Davidson NE, Zhou Q (2010) Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis 31: 382-387. doi:10.1093/carcin/bgp308. PubMed: 19995796. bgp308 .PII;Available: . doi:10.1093/carcin/bgp308
42. Moore R, Faller DV (2012) SIRT1 represses estrogen-signaling, ligand-independent ERalpha-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol.
43. Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Prakasam et al Gnana. (2011) SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor {alpha} in breast cancer. Cancer Res 71: 6654-6664. doi:10.1158/0008-5472.CAN-11-1446. PubMed: 21920899.
44. Li L, Yuan L, Luo J, Gao J, Guo J et al. (2013) MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 13: 109-117. PubMed: 22623155.
45. Lim JH, Lee YM, Chun YS, Chen J, Kim JE et al. (2010) Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1alpha. Mol Cell 38: 864-878. doi:10.1016/j.molcel.2010.05.023. PubMed: 20620956.
46. Tang BL (2010) Sirt1 and cell migration. Cell Adh Migr 4: 163-165. 10972 [pii]
47. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, et al. (2013) SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis. Cell Rep 3: 1175-1186.S2211-1247(13)00126-5 [pii];Available online at: 10.1016/j.celrep.2013.03.019 [doi]
48. Lee JS, Park KY, Min HG, Lee SJ, Kim JJ et al. (2010) Negative regulation of stress-induced matrix metalloproteinase-9 by Sirt1 in skin tissue. Exp Dermatol 19: 1060-1066. doi:10.1111/j.1600-0625.2010.01129.x. PubMed: 20812964. EXD1129 . PII;Available: . doi:10.1111/j.1600-0625.2010.01129.x
49. Gabay O, Zaal KJ, Sanchez C, Dvir-Ginzberg M, Gagarina V, et al. (2013) Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine epub ahead of print. S1297-319X(13)00021-3 [pii];Available online at: 10.1016/j.jbspin.2013.01.001 [doi]